At a time when addiction field professionals and advocates await a decision on the possible rescheduling of marijuana, a report from Congress's Government Accountability Office (GAO) has uncovered gaps in the overall evaluations conducted by the federal agencies involved in all drug scheduling decision‐making processes.
No takes yet. Share an insight, caveat, or question.
Gary A. Enos (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: